Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 18/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18825236 | 1.00 | DHODH (1.00) | DHODHGAAKMT2ASMN1; SMN2 | |
| SCHEMBL18825254 | 0.92 | DHODH (1.00) | DHODHGAAKMT2ASMN1; SMN2 | |
| SCHEMBL18851187 | 0.92 | DHODH (1.00) | DHODHGAAKMT2ASMN1; SMN2 | |
| SCHEMBL23934837 | 0.91 | DHODH (1.00) | DHODHGAAKMT2ASMN1; SMN2 | |
| SCHEMBL18850967 | 0.91 | DHODH (1.00) | DHODH | |
| SCHEMBL18825125 | 0.91 | DHODH (1.00) | DHODH | |
| SCHEMBL18825207 | 0.91 | DHODH (1.00) | DHODHGAAKMT2ASMN1; SMN2 | |
| SCHEMBL18825211 | 0.89 | DHODH (1.00) | DHODHGAAKMT2ASMN1; SMN2 | |
| SCHEMBL18825206 | 0.89 | DHODH (1.00) | DHODHGAAKMT2ASMN1; SMN2 | |
| SCHEMBL23934835 | 0.89 | DHODH (1.00) | DHODHGAAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795157-B2 | Tetrahydroindazoles and medical uses thereof | GENASE THERAPEUTICS B.V. (NL) | 2023-10-24 | — | — | US | disclosed |
| US-11795157-B2 | Tetrahydroindazoles and medical uses thereof | GENASE THERAPEUTICS B.V. (NL) | 2023-10-24 | — | — | US | disclosed |
| US-11795157-B2 | Tetrahydroindazoles and medical uses thereof | GENASE THERAPEUTICS B.V. (NL) | 2023-10-24 | — | — | US | disclosed |
| EP-3974424-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | Genase Therapeutics B.V. (NL) | 2022-03-30 | — | — | EP | disclosed |
| EP-3974424-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | Genase Therapeutics B.V. (NL) | 2022-03-30 | — | — | EP | disclosed |
| EP-3371172-B1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | GENASE THERAPEUTICS B V (NL) | 2021-10-20 | — | — | EP | disclosed |
| EP-3371172-B1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | GENASE THERAPEUTICS B V (NL) | 2021-10-20 | — | — | EP | disclosed |
| CN-108349947-B | Tetrahydroindazoles and pharmaceutical uses thereof | 格纳赛治疗有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210230141-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | GENASE THERAPEUTICS B.V. (NL) | 2021-07-29 | — | — | US | disclosed |
| US-20210230141-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | GENASE THERAPEUTICS B.V. (NL) | 2021-07-29 | — | — | US | disclosed |
| US-10889564-B2 | Tetrahydroindazoles and medical uses thereof | GENASE THERAPEUTICS B.V. (NL) | 2021-01-12 | — | — | US | disclosed |
| US-10889564-B2 | Tetrahydroindazoles and medical uses thereof | GENASE THERAPEUTICS B.V. (NL) | 2021-01-12 | — | — | US | disclosed |
| US-20190152943-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | GENASE THERAPEUTICS B.V. (NL) | 2019-05-23 | — | — | US | disclosed |
| US-20190152943-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | GENASE THERAPEUTICS B.V. (NL) | 2019-05-23 | — | — | US | disclosed |
| EP-3371172-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | Lain, Sonia (SE) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017077280-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | LAIN SONIA (SE) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017077280-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | LAIN SONIA (SE) | 2017-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889564-B2 | Tetrahydroindazoles and medical uses thereof | CYP11B2, CYP11B1, CYP1A1 | DHODH 542/4885GAA 2741/4885KMT2A 2453/4885 |
| US-20210230141-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | CYP11B2, CYP11B1, CYP3A43 | DHODH 574/4885GAA 2820/4885KMT2A 2515/4885 |
| US-11795157-B2 | Tetrahydroindazoles and medical uses thereof | CYP11B2, CYP11B1, CYP3A43 | DHODH 574/4885GAA 2820/4885KMT2A 2515/4885 |
| US-20190152943-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | CYP11B2, CYP11B1, CYP1A1 | DHODH 542/4885GAA 2741/4885KMT2A 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.